Sepracor looks to benefit its new owners
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma's new US subsidiary, Sepracor, expects to be debt free by the end of this year and is forecasting full-year non-GAAP revenues of $1.23-1.28 billion, compared with $1.29 billion in 2008.